Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(1-phenyl-propyl)-formamide is a small molecule compound belonging to the class of phenylpropanes, characterized by a phenylpropane moiety attached to a formamide group. It has the molecular formula C10H13NO and a molecular weight of approximately 163.22 g/mol[4][5][6]. The compound is considered experimental and has not been approved for any therapeutic use in the US or elsewhere[1]. Its primary mechanism of action is reported as an inhibitor of the capsid scaffolding protein (HHV-5), suggesting potential antiviral activity against human herpesvirus 5 (cytomegalovirus)[1]. There are no known clinical trials, approved indications, or marketed formulations for this drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(1-phenyl-propyl)-formamide.